title: Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial.
abstract: The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC.
authors.affiliation: Department of Internal Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Lederman
authors.forename: A N
authors.initials: AN
authors.lastname: Tenaglia
authors.forename: R D
authors.initials: RD
authors.lastname: Anderson
authors.forename: J B
authors.initials: JB
authors.lastname: Hermiller
authors.forename: K
authors.initials: K
authors.lastname: Rocha-Singh
authors.forename: F O
authors.initials: FO
authors.lastname: Mendelsohn
authors.forename: W R
authors.initials: WR
authors.lastname: Hiatt
authors.forename: T
authors.initials: T
authors.lastname: Moon
authors.forename: M J
authors.initials: MJ
authors.lastname: Whitehouse
authors.forename: B H
authors.initials: BH
authors.lastname: Annex
mesh_terms: D004311:Double-Blind Method; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012107:Research Design
chemical_list: D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2